Colin Baigent

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi request reprint Which cardiovascular risk factors matter in chronic kidney disease?
    Colin Baigent
    Clinical Trial Service Unit and Epidemiological Studies Unit CTSU, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK
    Nephrol Dial Transplant 22:9-11. 2007
  2. pmc Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis
    Marion Mafham
    Clinical Trial Service Unit, University of Oxford, Oxford, United Kingdom
    PLoS ONE 6:e25920. 2011
  3. doi request reprint Ensuring trial validity by data quality assurance and diversification of monitoring methods
    Colin Baigent
    Clinical Trial Service Unit and Epidemiological Studies Unit, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF
    Clin Trials 5:49-55. 2008
  4. ncbi request reprint Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trials
    Colin Baigent
    Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford, UK
    Semin Dial 20:498-503. 2007
  5. doi request reprint Randomization is essential for progress in transplant medicine
    Colin Baigent
    Clinical Trial Service Unit and Epidemiological Studies Unit CTSU, University of Oxford, Oxford, United Kingdom
    Transplantation 86:26-7. 2008
  6. pmc Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
    Colin Baigent
    CTSU, Oxford University, Oxford, UK
    Lancet 373:1849-60. 2009
  7. pmc Aspirin for everyone older than 50? Against
    Colin Baigent
    Clinical Trial Service Unit and Epidemiological Studies Unit, Radcliffe Infirmary, Oxford OX2 6HE
    BMJ 330:1442-3. 2005
  8. ncbi request reprint First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease
    Colin Baigent
    Clinical Trial Service Unit, Oxford University, Oxford, UK
    Am J Kidney Dis 45:473-84. 2005
  9. ncbi request reprint Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials
    Colin Baigent
    Clinical Trial Service Unit and Epidemiological Studies Unit, Radcliffe Infirmary, Woodstock Road, Oxford, OX2 6HE, UK
    Curr Opin Nephrol Hypertens 13:601-5. 2004
  10. ncbi request reprint The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD
    Martin Landray
    Clinical Trial Service Unit, University of Oxford, Churchill Hospital, Oxford, UK
    Am J Kidney Dis 47:385-95. 2006

Detail Information

Publications30

  1. ncbi request reprint Which cardiovascular risk factors matter in chronic kidney disease?
    Colin Baigent
    Clinical Trial Service Unit and Epidemiological Studies Unit CTSU, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK
    Nephrol Dial Transplant 22:9-11. 2007
  2. pmc Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis
    Marion Mafham
    Clinical Trial Service Unit, University of Oxford, Oxford, United Kingdom
    PLoS ONE 6:e25920. 2011
    ..We used a novel method to summarise the published results...
  3. doi request reprint Ensuring trial validity by data quality assurance and diversification of monitoring methods
    Colin Baigent
    Clinical Trial Service Unit and Epidemiological Studies Unit, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF
    Clin Trials 5:49-55. 2008
    ....
  4. ncbi request reprint Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trials
    Colin Baigent
    Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford, UK
    Semin Dial 20:498-503. 2007
    ....
  5. doi request reprint Randomization is essential for progress in transplant medicine
    Colin Baigent
    Clinical Trial Service Unit and Epidemiological Studies Unit CTSU, University of Oxford, Oxford, United Kingdom
    Transplantation 86:26-7. 2008
    ..Even after adjustment, nonrandomized studies may have large biases, so are not a suitable alternative to large randomized trials...
  6. pmc Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
    Colin Baigent
    CTSU, Oxford University, Oxford, UK
    Lancet 373:1849-60. 2009
    ..Low-dose aspirin is of definite and substantial net benefit for many people who already have occlusive vascular disease. We have assessed the benefits and risks in primary prevention...
  7. pmc Aspirin for everyone older than 50? Against
    Colin Baigent
    Clinical Trial Service Unit and Epidemiological Studies Unit, Radcliffe Infirmary, Oxford OX2 6HE
    BMJ 330:1442-3. 2005
  8. ncbi request reprint First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease
    Colin Baigent
    Clinical Trial Service Unit, Oxford University, Oxford, UK
    Am J Kidney Dis 45:473-84. 2005
    ..Patients with chronic kidney disease are at increased risk for cardiovascular disease, but the efficacy and safety of simvastatin and aspirin are unknown in this patient group...
  9. ncbi request reprint Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials
    Colin Baigent
    Clinical Trial Service Unit and Epidemiological Studies Unit, Radcliffe Infirmary, Woodstock Road, Oxford, OX2 6HE, UK
    Curr Opin Nephrol Hypertens 13:601-5. 2004
    ..This review outlines the limited information currently available on the effects of statins among patients with chronic kidney disease, and summarizes the ongoing randomized trials designed to address this question...
  10. ncbi request reprint The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD
    Martin Landray
    Clinical Trial Service Unit, University of Oxford, Churchill Hospital, Oxford, UK
    Am J Kidney Dis 47:385-95. 2006
    ..In preparation for such a trial, we assessed the biochemical efficacy, safety, and tolerability of adding ezetimibe, 10 mg/d, to simvastatin, 20 mg/d, as initial therapy for such patients...
  11. doi request reprint Analyses of cancer data from three ezetimibe trials
    Richard Peto
    Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford University, Oxford, United Kingdom
    N Engl J Med 359:1357-66. 2008
    ..gov number, NCT00092677) has raised the hypothesis that adding ezetimibe to statin therapy for larger LDL cholesterol reductions might increase the incidence of cancer...
  12. pmc The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
    Colin Baigent
    Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, UK
    Lancet 377:2181-92. 2011
    ..The SHARP trial aimed to assess the efficacy and safety of the combination of simvastatin plus ezetimibe in such patients...
  13. pmc Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study
    Martin J Landray
    Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, UK
    Am J Kidney Dis 56:1082-94. 2010
    ..Validated prediction scores are required to assess the risks of end-stage renal disease (ESRD) and death in individuals with chronic kidney disease (CKD)...
  14. pmc Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials
    Patricia M Kearney
    Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford OX3 7LF
    BMJ 332:1302-8. 2006
    ..To assess the effects of selective cyclo-oxygenase-2 (COX 2) inhibitors and traditional non-steroidal anti-inflammatory drugs (NSAIDs) on the risk of vascular events...
  15. ncbi request reprint A practical method of measuring glomerular filtration rate by iohexol clearance using dried capillary blood spots
    Marion M Mafham
    Renal Studies Group, Clinical Trial Service Unit, Old Road Campus, Oxford, UK
    Nephron Clin Pract 106:c104-12. 2007
    ..Exogenous tracer-based methods of measuring glomerular filtration rate (GFR) are difficult to perform, whilst creatinine-based estimation formulae are inaccurate...
  16. ncbi request reprint Statins: are any questions unanswered?
    Patricia M Kearney
    Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford, UK
    Curr Opin Lipidol 17:418-25. 2006
    ..To summarize recent and ongoing randomized trials of statin therapy for the prevention of major vascular events...
  17. pmc Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP)
    Richard Haynes
    Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
    Am J Kidney Dis 64:40-8. 2014
    ..The relevance of the cause of kidney disease to prognosis among patients with chronic kidney disease is uncertain...
  18. ncbi request reprint Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study
    Martin J Landray
    Clinical Trial Service Unit, University of Oxford, Oxford, UK
    Am J Kidney Dis 43:244-53. 2004
    ..Studies in the general population suggest that low-grade inflammation, endothelial dysfunction, and platelet activation are associated with an increased risk of cardiovascular events...
  19. pmc Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol
    Richard Haynes
    Clinical Trial Service Unit and Epidemiological Studies Unit, Richard Doll Building, Old Road Campus, Roosevelt Drive, Headington Oxford OX3 7LF, UK
    Transplant Res 2:7. 2013
    ..CNI exposure could be minimized by using more potent induction therapy or alternative maintenance therapy to remove CNIs completely. However, the safety and efficacy of such strategies are unknown...
  20. ncbi request reprint Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal
    Colin Baigent
    Clinical Trial Service Unit, Radcliffe Infirmary, Oxford, UK
    Arthritis Rheum 48:12-20. 2003
  21. ncbi request reprint Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Carlo Patrono
    Catholic University School of Medicine, Largo F Vito 1, Rome, Italy
    Chest 133:199S-233S. 2008
    ....
  22. ncbi request reprint Cross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of pre-dialysis patients. The chronic renal impairment in Birmingham (CRIB) study
    Daniel Zehnder
    Department of Nephrology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK
    Nephron Clin Pract 107:c109-16. 2007
    ..However, it is unclear at what stage of chronic kidney disease (CKD) these abnormalities develop...
  23. pmc Article makes simple errors and could cause unnecessary deaths
    Colin Baigent
    BMJ 324:167. 2002
  24. ncbi request reprint Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis
    Charles H Hennekens
    Center of Excellence, Florida Atlantic University, USA
    Nat Clin Pract Cardiovasc Med 3:4-5. 2006
  25. ncbi request reprint Low-dose aspirin for the prevention of atherothrombosis
    Carlo Patrono
    Department of Pharmacology, University of Rome La Sapienza, Rome, Italy
    N Engl J Med 353:2373-83. 2005
  26. ncbi request reprint Cholesterol and the risk of renal dysfunction in apparently healthy men
    Elke S Schaeffner
    Divisions of Preventive Medicine, and Aging, and Cardiovascular Disease, and Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, USA
    J Am Soc Nephrol 14:2084-91. 2003
    ..5 mg/dl...
  27. ncbi request reprint B vitamins for the prevention of vascular disease: insufficient evidence to justify treatment
    Colin Baigent
    JAMA 298:1212-4. 2007
  28. ncbi request reprint [Expert consensus document on the use of antiplatelet agents]
    Carlo Patrono
    Rev Esp Cardiol 57:963-80. 2004
  29. ncbi request reprint Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology
    Carlo Patrono
    ESC Task Force on Antiplatelets, University of Rome La Sapienza, II Facolta di Medicina e Chirurgia, Via di Grottarossa, 1035, 00189 Roma, Italy
    Eur Heart J 25:166-81. 2004
  30. ncbi request reprint Anticoagulants in heart disease: current status and perspectives
    Raffaele De Caterina
    Institute of Cardiology, G d Annunzio University Chieti, Ospedale S Camillo de Lellis, Chieti, Italy
    Eur Heart J 28:880-913. 2007